Hormonal
GLP-1 receptor agonists (GLP-1RAs) induce significant weight loss in adults with obesity or overweight by acting on the central nervous system to increase satiety and on the gastrointestinal tract to delay gastric emptying.
GLP-1 medications (like Semaglutide or Tirzepatide) are highly effective for weight loss, often achieving 15-25% body weight reduction in clinical trials. They work by reducing appetite and slowing digestion. These are prescription medications, not supplements. They require long-term use to maintain weight loss, as stopping often leads to regain. They are generally safe but can cause gastrointestinal side effects. Consult a doctor to see if you are a candidate.
GLP-1RA 的减重机制包括：(1) 作用于中枢，抑制食欲，增加下丘脑弓状核饱食信号的水平，并降低抑制信号，从而增强饱腹感，减少热量摄入；(2) 作用于胃肠道，延缓胃排空和胃肠蠕动，减少胃泌素刺激的胃酸分泌。
Why this rating
The paper cites multiple large-scale, randomized, double-blind, placebo-controlled clinical trials (e.g., STEP 1, SURMOUNT-1) with significant sample sizes.
Source
The glucagon-like peptide-1 (GLP-1) drugs poised to conquer obesity
Jun Yin et al. · Chinese Science Bulletin (Chinese Version) · 2024
DOI 10.1360/tb-2024-0417
More from this paper
- GLP-1 receptor agonists provide cardiovascular benefits for patients with obesity, even those without diabetes, by reducing the risk of major adverse cardiovascular events.Strong
- Multi-receptor agonists (e.g., Tirzepatide, Retatrutide) achieve greater weight loss than single-target GLP-1RAs by simultaneously activating multiple gut hormone receptors (GLP-1R, GIPR, GCGR).Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →